Analytical Data
-
基因名
EDIL3
-
简介
EDIL3 Protein enhances endothelial cell adhesion by interacting with the alpha-v/beta-3 integrin receptor, while also inhibiting the formation of vascular-like structures. Its role suggests involvement in the regulation of vascular morphogenesis during embryonic development. EDIL3 Protein, Human (HEK293, His) is the recombinant human-derived EDIL3 protein, expressed by HEK293 , with C-6*His labeled tag.
- Application
-
别名
EGF-Like Repeats and Discoidin I-Like Domains 3; EDIL3
-
种属
Human
-
表达系统
HEK293
-
标签
C-6*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O43854-1
-
表达区间
D24-E480
-
蛋白长度
Full Length of Isoform-1 Mature Protein
-
分子量
56 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EDIL3, or EGF-like repeats and discoidin I-like domains 3, is a member of the EGF-like protein family and has recently attracted attention in molecular biology and cancer research due to its multifunctional roles. Initially identified as a protein involved in extracellular matrix remodeling, EDIL3 has been implicated in various biological processes including cell adhesion, migration, and proliferation. Its expression is often associated with tumor progression and metastasis, making it a potential biomarker for various cancers. Research has suggested that EDIL3 may modulate the tumor microenvironment and interact with various signaling pathways, thereby influencing cancer cell behavior and the immune response. The recombinant protein forms of EDIL3 are being explored for their potential therapeutic applications, particularly in targeted cancer therapies and regenerative medicine. Ongoing studies aim to elucidate the precise molecular mechanisms by which EDIL3 exerts its effects and to assess its viability as a therapeutic target, with the goal of improving treatment outcomes for patients with malignancies where EDIL3 overexpression is observed. Understanding the role of EDIL3 in these contexts not only contributes to our knowledge of tumor biology but may also lead to innovative strategies in cancer treatment and tissue engineering.
